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Ribonuclease (RNase) with its catalytic enzyme activity to degrade RNAs has
been shown as a diagnostic serum marker for pancreatic cancer and has also been
suspected to have an unidentified cell surface receptor. Epidermal growth factor
receptor (EGFR), a well-characterized receptor tyrosine kinase is an effective
therapeutic target in multiple cancer types. However, clinical trials targeting EGFR
have not demonstrated improved therapeutic efficacy in pancreatic cancer. Here,
we show that both bovine pancreatic RNase A (bRNaseA) and human RNase 5
(hRNase5) act as EGFR ligands and directly activate EGFR to promote epithelialmesenchymal transition. This ligand-like activity is independent of RNases’
enzymatic activity. In addition, Gln93 and Tyr94 of hRNase5, which are highly
conserved between hRNase5 and EGF, are critical for efficient binding to EGFR. A
statistically positive correlation between hRNase5 and activated EGFR expression
in human pancreatic tissue microarrays further supports the pathological relevance
of hRNase5. Strikingly, hRNase5 also enhances resistance to cetuximab therapy in
pancreatic cancer. Thus, there may be an interplay between serum RNase and
overexpressed EGFR in human cancers, especially in pancreatic cancer, that leads

v

to aggressive cancer behaviors. Our findings uncover a potential opportunity for
therapeutic intervention by rational combination therapy of hRNase5 inhibition and
cetuximab.
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Chapter 1
Introduction

1

1.1 Structural perspective of EGFR and its family members
Growth factors and their cognate receptors play essential roles in governing life
and death of cells and organisms. Among them, the epidermal growth factor
receptor (EGFR/ErbB1/HER1) and its family members including ErbB2 (HER2/Neu),
ErbB3 (HER3) and ErbB4 (HER4), have long been recognized as a primordial type
of receptor tyrosine kinases which contribute to key steps in both human physiology
and diseases (Hynes & Lane, 2005; Lemmon & Schlessinger, 2010). As single
chain transmembrane glycoproteins, the epidermal growth factor receptor family
preserves structural resemblance within its four members, which are composed of
an N-terminal extracellular ligand-binding ectodomain, a lipophilic transmembrane
domain, a short juxtamembrane region, a tyrosine kinase domain and a tyrosinerich regulatory domain at C-terminal. To date, both EGFR and HER4 are reported
as complete functional receptor tyrosine kinases with corresponding ligands and
functional tyrosine kinase domains. However, HER2 is an orphan receptor without
cognate ligands found so far (Brennan et al., 2000), and HER3 is not a functional
tyrosine kinase since it loses intrinsic kinase activities (Guy et al., 1994). The Nterminal extracellular domain can be further divided into four subdomains which are
L1 (Leucine-rich/domain I), CR1 (Cysteine-rich/domain II), L2 (Leucine-rich/domain
III) and CR2 (Cysteine-rich/domain IV) in a linear order from N- to C-terminal.
Domain I and III are responsible for direct ligand binding to receptors, whereas
domain II and IV constitute dimerization loop and contribute to receptor-receptor
interaction. Without ligand stimulation, domain II and IV are bound with each other
through intramolecular binding, this interaction forces the receptor in a closed and
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inactive monomer conformation which can keep domain I and III away from
extracellular ligands. However, in the presence of a soluble ligand, domain I and III
can be bound by the ligand in a direct manner, this conformational change can
remove the intramolecular interaction between domain II and IV and shift a receptor
from a closed and inactive conformation to an open and active orientation. In an
open and active orientation, the dimerization region from domain II of one receptor
can be exposed and associated with the other receptor at the same region to further
facilitate the formation of a receptor dimer. The balance between the open and
closed conformation of a receptor is usually kept at steady state and can be
modulated by a variety of ligands binding to switch monomeric receptors to become
either homo-dimers or hetero-dimers, depending on the type of ligands and
corresponding receptors (Eccles, 2011).

1.2 Endocytic trafficking of EGFR
When receptors are bound by ligands to cause their conformational change and
dimerization, they will be further internalized as vesicles and undergo endosomal
sorting and trafficking to different subcellular location inside the cell (Conner &
Schmid, 2003; Doherty & McMahon, 2009; Sorkin & von Zastrow, 2009).
Internalization of receptors can occur through clathrin-dependent or clathrinindependent pathways to form vesicles, followed by adaptor proteins (AP2) and
growth factor receptor-bound protein 2 (Grb2) binding and fusion with early
endosomes (Mayor & Pagano, 2007; Orth et al., 2006; Sigismund et al., 2005;
Sorkin, 2004). Concomitant recruitment of E3 ubiquitin ligase Cbl to receptors
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through direct or indirect binding (Grb2-dependent) will catalyze receptor
ubiquitination in either monomeric or polymeric forms on certain lysine residues of
their kinase domain, which can be further recognized by ubiquitin-binding proteins
such as epsin1 and Eps15 for subsequent sorting and targeting through endosomal
sorting complex required for transport (ESCRT) within multivesicular bodies and
subject to lysosomal degradation (Gruenberg & Stenmark, 2004; Saftig &
Klumperman, 2009; Sorkin & Goh, 2009; Williams & Urbe, 2007; Woodman, 2009).
Under certain circumstances such as pH-dependent decreased stability of ligandreceptor complex or AMSH-mediated deubiquitination process, activated receptors
can go through recycling pathway to escape from lysosomal degradation (Baldys &
Raymond, 2009). As reported by previous studies, recycling of receptor kinases can
occur via Rab4- and Rab35-dependent pathway to plasma membrane or Rab11regulated route through perinuclear endocytic recycling compartment (ERC)
(Ceresa, 2006; Grant & Donaldson, 2009; Maxfield & McGraw, 2004). Increased
receptor recycling instead of lysosomal degradation after its activation may prolong
its signaling duration and succeeding mitogenic effects.
Notably, a growing body of evidence has shown that other than traditional
routes to lysosomal degradation and endocytic recycling, EGFR and other
membrane receptors can undergo nuclear translocation through a retrograde
pathway (Brand et al., 2013; Carpenter & Liao, 2009; Lin et al., 2001; Lo, 2010;
Massie & Mills, 2006; Mosesson et al., 2008; Ni et al., 2001; Offterdinger et al.,
2002; Seshacharyulu et al., 2012; Wang & Hung, 2012; Wang et al., 2010a). Inside
the nucleus, EGFR can serve as a kinase, transcription factor or protein scaffold to
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modulate nuclear signaling and gene expression. This alternative route of EGFR to
nucleus can contribute to DNA repair, replication of tumor cells and confer
resistance to chemo- and radio-therapies (Dittmann et al., 2011; Huang et al., 2011;
Huang & Hung, 2009; Wang et al., 2006; Wang et al., 2010b). In addition, nuclear
EGFR has the clinical relevance to be associated with poor patient prognosis in
diverse cancers, including breast, ovarian, and oropharyngeal and esophageal
squamous cell cancers (Hadzisejdic et al., 2010; Hoshino et al., 2007; Lo et al.,
2005; Psyrri et al., 2008; Psyrri et al., 2005; Xia et al., 2009) (Figure 1-1).

1.3 Ligands of ErbB family
A group of ligands are known to activate ErbB family members including EGF,
transforming growth factor alpha (TGF-α), amphiregulin (AR), betacellulin (BTC),
heparin-binding EGF-like growth factor (HB-EGF), epiregulin (EPR), epigen (EPG),
neuregulins 1-4 (NRGs), neuroglycan C (NGC) and tomoregulin (TR) (Citri &
Yarden, 2006; Harris et al., 2003). These ligands are expressed as plasma
membrane-anchored precursor proteins and are processed to mature forms via
proteolytic release by certain metalloproteinase such as TACE/ADAM17 and
ADAM10, etc (Nakamura et al., 1995). Among them, EGF, TGF-α, AR and EPG are
specific ligands to EGFR, whereas BTC, HB-EGF and EPR can bind to both EGFR
and HER4. Moreover, NGC is a specific ligand to HER3, and both NRG3 and NRG4
are particular ligands to HER4. NRG1 and NRG2 can bind to either HER3 or HER4.
To date, there is no specific ligand found for HER2 and its activation are reported to
be caused by either receptor overexpression or heterodimerization with another
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Figure 1-1. ERBB trafficking.
Exposing

the

cell

to

epidermal

growth

factor

(EGF)

results

in

the

autophosphorylation of surface EGF receptor (EGFR), which might result in EGFR
moving out of lipid rafts. This activation also results in the ubiquitylation of the
receptor and its removal (endocytosis) from the cell surface into an early endosomal
compartment. The ligand-bound receptor activates several signaling pathways at
the cell surface by activating Ras and phospholipase Cγ (PLCγ). EGFR interacts
with and activates signalling molecules while its cytoplasmic tail projects into the
cytoplasm, as occurs in the early endosome. From the early endosome the receptor
6

can be recycled back to the cell surface (a) or sorted into the late endosome and
the vesicles within this compartment that are called multivesicular bodies (b). If
sorted into multivesicular bodies, the cytoplasmic tail is occluded from the
cytoplasm and this prevents further activation of signalling cascades. Following a
fusion event between the late-endosomal and lysosomal compartments the
internalized receptor is incorporated into the lysosome and degraded. A third
possibility is that, having been internalized and incorporated into the early
endosome, the receptor is delivered to the nucleus (c). The route that is taken to the
nucleus by ERBBs is unclear, but might include proteolytic cleavage, membrane
fusion or chaperone-mediated dissociation of the receptor from the membrane. This
is potentially a direct route to mediate changes in gene expression and DNA repair
in response to stimuli. Nuclear translocation is also a property of certain adaptor
proteins that are associated with early endosomes, including APPL (adaptor protein
containing a pleckstrin homology domain, a PTB domain and a leucine zipper motif)
and HIP1 (huntingtin-interacting protein 1). Additional, and less-common, trafficking
routes for cargo arriving in the early endosome include retrograde trafficking steps
to compartments such as the endoplasmic reticulum (ER) and Golgi apparatus that
are associated with the biosynthesis and post-translational modification of proteins.
Viruses and toxins commonly use these trafficking routes to ultimately gain access
to the cytoplasm by expulsion from the ER. P, phosphate; Ub, ubiquitin. (This figure
was adapted from MASSIE, C. & MILLS, I. G. (2006). The developing role of
receptors and adaptors. Nat Rev Cancer, 6(5), 403-409; the permission was
received from the journal.)
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receptors including EGFR, HER3 or HER4 through their corresponding ligand
binding and stimulation (Harris et al., 2003) (Figure 1-2).

1.4 Activation of EGFR signaling
Dimerization of receptors leads to their auto-phosphorylation on particular
tyrosine residues through a reciprocal manner, further recruiting protein adaptors,
effector proteins and kinase substrates to trigger downstream signaling network. To
initiate the phosphotyrosine-based signaling cascade, phosphotyrosine residues
from a receptor kinase are specifically recognized by a Src homology 2 (SH2) and
phosphotyrosine-binding domain from an adaptor protein. This phosphotyrosinebased molecular recognition

can

lead to adaptor and effector proteins

phosphorylation and elevate their activities, further provoking subsequent
occurrence of signaling events including the RAS-RAF-MEK-ERK pathway,
phosphoinositide

3-kinase

(PI3K)-AKT

(Protein

kinase

B/PKB)

signaling,

phospholipase C gamma (PLCγ)-protein kinase C (PKC) pathway, and signal
transducer and activator of transcription (STAT) activation (Yarden, 2001). These
signaling pathways act as mediators amplify and transmit the original stimuli from
the receptor at plasma membrane to intracellular space including cytosol and
subcellular organelles, eventually to the nucleus to regulate DNA replication, gene
transcription and translation, etc. Through these signaling cascades and molecular
interaction events, an ErbB receptor-triggered signaling can modulate and
contribute to normal cellular events including proliferation, migration, differentiation,
development, etc (Citri & Yarden, 2006; Huang et al., 2009). On the other hand, its
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Figure 1-2. Heterodimerization, ligand binding and signaling in the EGFR and
ERBB family.
(a) EGFR is a 170 kDa transmembrane protein of the HER family of receptors. Each
receptor contains an extracellular ligand-binding domain, a transmembrane
lipophilic domain and an intracellular tyrosine kinase domain and, except for HER3,
relies upon heterodimerization for transphosphorylation. No ligand for HER2 has
9

been identified. Ligand binding induces autophosphorylation and causes activation
of downstream signaling pathways. Ligands are indicated by circles, PI3K binding
sites are indicated by red squares. (b) Diagram of EGFR protein. The extracellular
domain of EGFR comprises 621 amino acids and consists of four different subunits,
RI–RIV. RI is important in ligand-induced dimerization; RII and RIV are rich in
cysteine residues. RIII includes the EGF-binding domain. The intracellular region
contains the tyrosine kinase domain and the C-terminus, which has six
autophosphorylation sites. (c) The most widely known and best-characterized RAS
signaling pathways include MAPK–ERK, the MAPK–JNK and p38 pathways. MAPK
cascades are activated through a large variety of extracellular signals, including
growth factors, differentiation factors and stress-induced factors. Abbreviations: HBEGF, heparin-binding EGF-like growth factor; TM, transmembrane region. (This
figure was adapted from LINARDOU, H., DAHABREH, I. J., BAFALOUKOS, D.,
KOSMIDIS, P. & MURRAY, S. (2009). Somatic EGFR mutations and efficacy of
tyrosine kinase inhibitors in NSCLC. Nat Rev Clin Oncol, 6(6), 352-366; the
permission was received from the journal.)
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dysregulation can lead to multiple types of human malignancies and diseases,
including cancers.

1.5 EGFR genetic alterations in cancers
Enormous studies and clinical evidence have demonstrated that EGFR plays a
key role in various types of cancer development, including lung, head and neck,
breast, ovarian, colon and pancreatic cancers, etc. Ectopic expression of EGFR can
lead to transformation of mouse NIH3T3 cells in vitro through ligand-dependent
manner. Blockage of EGFR signaling impedes growth of multiple types of cancer
cells both in vitro and in vivo. Genetic alternations of EGFR such as gene
amplification or somatic mutation are frequently observed in both clinical samples
and tumor cell lines derived from patients with different types of cancers. In average,
EGFR gene amplification can be detected in about 40% of human primary
glioblastoma multiforme (GBM) (Hatanpaa et al., 2010; Lopez-Gines et al., 2010)
and 5-10% Non-small cell lung cancer (NSCLC) (Gazdar, 2009; Linardou et al.,
2009). Activating deletions of EGFR have also been found in a significant
population of GBM patients and associated with poor prognosis. N-terminal
truncations and deletions of EGFR are reported including EGFRvI (N-terminal
truncation), EGFRvII (exon 14-15 deletion), EGFRvIII (exon 2-7 deletion), EGFRvIV
(exon 25-27 deletion) and EGFRvV (C-terminal truncation). Among them, EGFRvIII
is a major mutant which is known to play a key role in GBM pathogenesis
(Shinojima et al., 2003). In addition, it can be also detected in breast, ovarian,
prostate and lung cancers and participated in cancer progression. Activating
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mutations of EGFR kinase domain are also identified in 10-20% NSCLCs including
missense mutations (L858R, G719X and L861Q), in frame deletion of exon 19 or
insertion of exon 20, etc (Wieduwilt & Moasser, 2008).

1.6 EGFR-targeted therapies in cancers
Due to its integral role in the pathogenesis of different types of tumors, inhibition
of EGFR signaling as a target therapy is developed for years and proved powerful in
certain clinical settings (Tomas et al., 2014). Both EGFR-specific monoclonal
antibodies (mAbs) and chemical compounds as EGFR tyrosine kinase inhibitors
(TKIs) are approved and prevalently used in clinics for different types of cancers
(Chong & Janne, 2013; Eccles, 2011; Wheeler et al., 2010). EGFR-specific mAbs
such as cetuximab (Erbitux/C225) and panitumumab (Vectibix) are generated to
bind to EGFR extracellular domain for preventing from their cognate ligand binding.
C225 is commonly used in colon cancers with wild type KRAS status, and it is also
applied in head and neck cancers which possess EGFR overexpression with higher
frequency (Mendelsohn & Baselga, 2000). On the other hand, the TKIs gefitinib
(Irresa) and erlotinib (Tarceva) are both actively applied in the clinical treatment of
NSCLC patients with EGFR activating mutations. Higher response rate and
extended survival time are reported for NSCLC patients with EGFR activating
mutations compared to those who do not have mutations treated with TKIs
(Seshacharyulu et al., 2012). In summary, several lines of evidence and studies
have suggested that application of anti-EGFR agents to certain types of tumors
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including colon, head and neck, NSCLC and pancreatic cancer confers benefits and
advantages in terms of overall survival or progression-free survival.

1.7 The role of EGFR in pancreatic cancer
Human pancreatic cancer, attributed to its high mortality rate and poor clinical
outcome, currently ranks fourth as cancer death cause in the United States. Due to
the early metastasis, late diagnosis and refractory to canonical therapies including
chemotherapy and radiotherapy, pancreatic cancer especially pancreatic ductal
adenocarcinoma (PDAC) is recognized as one of the most lethal malignancies
among human cancers in the last decades (Hidalgo, 2010). Massive efforts have
been made to characterize critical genetic alternation and signaling pathways
occurring with PDAC development. Based on genetic studies and transgenic mouse
models, it is believed that KRAS and INK4A mutation occur in the early stage of
PDAC development; follow by alternation of SMAD4 and p53 tumor suppressors
(Lunardi et al., 2014). Notably, two decent papers have recently reported that EGFR
is required for tumor initiation and development based on PDAC transgenic mouse
models (Ardito et al., 2012; Navas et al., 2012). EGFR depletion can impede PDAC
tumorigenesis in KRASG12D and CDKN2Aflox mice, whereas it doesn’t affect
KRASG12D-driven lung cancer progression. Interestingly, EGFR overexpression in
advanced pancreatic cancer is present from 30% to 95% depending on cases
examined. Moreover, several lines of evidence suggest that EGFR or EGF
expression has been found to be positively associated with PDAC metastasis in a
significant level. These previous research work point out EGFR may play a critical

13

role in PDAC tumor initiation and contribute to its development and metastasis.
However, how EGFR signaling regulates PDAC progression remains unclear and its
clinical impact awaits more follow-up studies and clinical trials to delineate. To date,
four Phase III trials in advanced PDAC using anti-EGFR target therapies combined
with conventional chemotherapeutic agents including gemcitabine or capecitabine
were completed (Heinemann et al., 2013; Moore et al., 2007; Philip et al., 2010; Van
Cutsem et al., 2009). The benefits from EGFR-targeted therapy are limited, and it
remains to be further pursued if it can be improved in the aid of certain predictive
biomarkers.

1.8 Bovine pancreatic RNase A
As a most well studied enzyme in 20th century and so far, bovine pancreatic
ribonuclease A (RNase A) has been established as a model system for research of
protein chemistry, enzymology and structure biology, etc. Ribonuclease A was first
identified by Ren’e Dubos in 1938, crystallized by Moses Kunitz’s group in 1940,
sequenced by Stanford Moore and William Stein in 1963 (through cooperation with
Anfinsen’s group), and synthesized through solid-phase by Merrifield’s group in
1969. Four Nobel Prizes were awarded (Anfinsen, Moore, Stein and Merrifield) for
their comprehensive and excellent work at RNase studies (Marshall et al., 2008;
Raines, 1998). RNase A is a pancreatic endonuclease which is secreted from β
cells at the islets of Langerhans. It can cleave phosphodiester bond at single strand
RNA between the 5’-ribose of a nucleotide and the phosphate group on a 3’-ribose
of the neighboring pyrimidine nucleotide, and further hydrolyze the formed 2’-3’-
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cyclic phosphate intermediate to generate 3’-nucleoside phosphate. It exerts
substrate preference for different bases on both 5’- and 3’-end of the broken
phosphodiester bond. At the 5’-position, RNase A displays higher enzymatic
efficiency in an order as A>G>C>U, whereas at the 3’-position, a pyrimidine is
required to be present and C is favored than U. Being a secretory enzyme produced
from pancreas, RNase A possess signal peptide on the very N-terminal (1-26 of
precursor protein) which is responsible for its secretion to extracellular space. In
native RNase A protein, there are four pairs of disulfide bonds (Cys26-Cys84,
Cys40-Cys110, Cys58-Cys110 and Cys65-Cys72) which contribute to its protein
folding and stability. The mature form of RNase A protein (124 amino acids)
contains a catalytic triad constituted ty amino acid residue His12, Lys41, and His119,
where His12 and His119 acts as a respective proton acceptor and donor, and Lys41
can provide a hydrogen bond to stabilize the transition state during catalysis
(Cuchillo et al., 2011).

1.9 Human RNase A family
In last decades, a family of vertebrate secretory ribonucleases with sequence
and structure homology to bovine RNase A has been found from the human
genome. In general, they are recognized as part of host defense system and
contribute to immunity especially innate immunity. To date, there are 13
ribonucleases are identified for the RNase A family which are produced and
secreted from various types of cell types including epithelial, endothelial and
immune cells, etc (Cho et al., 2005). Among them, human RNase 1 is the direct
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homologue of bovine RNase A according to their sequence and structure similarity
(Peracaula et al., 2000). The RNase A family can be divided into two groups; the
canonical ribonucleases (RNase 1-8) and non-canonical ribonucleases (RNase 913) (Sorrentino, 2010). In the group of canonical ribonucleases, they maintain
classical signal sequences for secretion, particular disulfide-bonded secondary and
tertiary structure, conserved active sites and His-Lys-His catalytic triad to exhibit
certain degree of catalytic activity against single strand RNA substrate (Cuchillo et
al., 2011; Yang et al., 2004). On the other hand, the non-canonical ribonucleases do
not act as functional enzymes because they encode either insertions, deletions or
mutation at certain essential residues although they still exert microbicidal activities
and contribute to host defense system (Cho et al., 2005; Sorrentino, 2010).

1.10 RNases in cancers
In addition to being participants in host defense system, expression of
ribonucleases have been demonstrated to be positively associated with cancer
occurrence and progression. Elevated ribonuclease activities were detected in
several types of cancers including lung, thyroid, breast, ovarian, kidney, colon and
pancreatic cancer (Matte et al., 2012; Reddi & Holland, 1976; Tello-Montoliu et al.,
2006). Compared to other types of cancers, pancreatic cancer is one of the most
studied malignancies with this observation since numerous studies have indicated
higher ribonuclease activities can be measured in patient serum compared to
control samples. Accordingly, ribonuclease activity was proposed to serve as early
diagnostic marker for pancreatic cancer in several studies (Kottel et al., 1978;
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Warshaw et al., 1980; Zhao et al., 1998) although some researchers argued it lacks
specificity to be useful. In addition to ribonuclease activities, specific members of
RNase A family including human RNase 1 and RNase 5 were reported to be
involved in the development of pancreatic cancer (Peracaula et al., 2000; Poon et
al., 2001; Reddi & Holland, 1976). Both human RNase 1 and RNase 5 protein can
be detected in the culture medium of pancreatic cancer cells, and specific isoforms
of human RNase 1 with distinct glycosylation pattern were merely detected in tumor
cell lines (Peracaula et al., 2003). Moreover, increased human RNase 5 was
correlated with pancreatic cancer occurrence and aggressiveness (Shimoyama et
al., 1996). In contrast to other members in the RNase A family, accumulated studies
have concluded human RNase 5 as an oncogenic protein which can induce blood
vessel formation in vitro and in vivo (Hu et al., 1997; Li et al., 2011; Yoshioka et al.,
2006). Because its potency to promote angiogenesis, it is also named angiogenin.

1.11 Human RNase 5 (angiogenin)
Human RNase 5 (angiogenin) was first isolated from culture medium of a
human colon cancer cell line HT-29. Like other RNase A family members, human
RNase 5 exhibits microbicidal function to protect from pathogen infection. However,
it is also a potent factor to stimulate angiogenesis . It is a close homologue of
human RNase 1 with 33% in sequence identity and 65% homology. Human RNase
5 contains a classical secretory signal sequence (1-24 of a precursor protein) and a
conserved catalytic triad (His13, Lys40 and His114 of the mature form with 123
amino acids) (Padhi et al., 2012; Strydom, 1998). In spite of its high similarity to
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human RNase 1 in tertiary structure, human RNase 5 exerts much lower enzymatic
activity than RNase 1 (105 -106 less in average) (Cho et al., 2005; Sorrentino, 2010).
However, it is demonstrated that ribonuclease activity is essential but not sufficient
for human RNase 5-induced angiogenesis (Hu, 1998). Its expression is increased
during inflammation, pregnancy and certain pathological conditions. Moreover, it
was showed that its expression is elevated in several malignant diseases and
multiple types of cancers including colon, prostate, ovarian and pancreatic cancer
(Matte et al., 2012; Tello-Montoliu et al., 2006). Several lines of evidence suggests
human RNase 5 can increase endothelial cell migration and proliferation through
initiating intracellular signaling pathways, such as PLCγ, AKT and ERK activation
(Kim et al., 2007; Liu et al., 2001). Previous studies also showed that after entry into
recipient cells, human RNase 5 can translocate to nucleus and increase rRNA
transcription (Ibaragi et al., 2009; Moroianu & Riordan, 1994). Correspondingly,
nuclear translocation of human RNase 5 is required for its provoked endothelial cell
proliferation and angiogenesis. To search for a potential surface receptor bound by
human RNase 5, researchers have demonstrated that human RNase 5 can bind to
α-actinin-2 on the surface of smooth muscle cells to promote their proliferation (Hu
et al., 2005). In addition, α-actin and 170-kDa cell surface receptor from endothelial
cells were identified to be a binding partner of human RNase 5 (Hu et al., 1997).
Binding to α-actin can lead to proteolytic activation, which may contribute to
basement membrane degradation (Hu et al., 1993). It is believed that this 170-kDa
surface receptor could be critical for human RNase 5-provoked signaling and
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angiogenic function. However, the identity of this receptor remains ambiguous and
awaits more studies to resolve the puzzle.
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Chapter 2
Material and Methods
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2.1 Materials
The following antibodies and chemicals were purchased commercially: antiEGFR antibodies (Ab-13, Thermo Scientific; 4267, Cell Signaling; ab62, Abcam);
AG1478, mouse IgG, bovine RNase A (bRNaseA), human EGF, anti-RNase1, actin,
and tubulin antibodies (Sigma); anti-bRNaseA (ab6611) and bRNaseA biotinylated
(ab20588) antibodies (Abcam); anti-myc antibody (Roche); anti-flag antibodies
(Sigma; Cell Signaling); TMB (3,3',5,5"-tetramethylbenzidine) substrate, stop
solution, anti-Akt, phospho-Akt, phospho-ERK1/2, phospho-EGFR (-Tyr992, Tyr1045, -Tyr1068, -Tyr1086, -Tyr1148, and -Tyr1173), phospho-ErbB2 (Tyr1221/1222 and -Tyr1248), EMT (Slug, Snail, E-cadherin, N-cadherin, Vimentin,
and ZEB-1), and GST antibodies (Cell Signaling); anti-ErbB-2 (Calbiochem); ELISA
96-well plate, BSA blocking solution, and anti-p68 RNA helicase antibody (Santa
Cruz Biotechnology); anti-phosphotyrosine (p-Tyr; 4G10) and ERK1/2 antibodies
(Millipore);

recombinant

human

RNase

5/angiogenin,

recombinant

human

EGFR/ErbB1 Fc Chimera (N-EGFR-Fc), Proteome Profiler Human Phospho-RTK
Array Kit, Streptavidin-HRP, anti-angiogenin (AB-265-NA), angiogenin biotinylated
(BAF265), EGF, and EGF biotinylated (BAF236) antibodies (R&D Systems);
gefitinib (ChemieTek); erlotinib (LC Labs); biotin-EGF and SYTO® RNASelectTM
green-fluorescent cell stain (Invitrogen); and DyLight 594 labeling kit (Thermo
Scientific). Cetuximab was obtained from the Clinic Pharmacy at MD Anderson
Cancer Center. The secondary antibodies were purchased from Jackson
ImmunoResearch Laboratories. For siRNA experiments, siRNA oligonucleotides
targeting EGFR, ErbB2, and nonspecific siRNA control were purchased from Sigma.
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The siRNA sequences were EGFR-siRNA-1: 5'-GACAUAGUCAGCAGUGACU-3';
EGFR-siRNA-2:

5'-GAUCUUUCCUUCUUAAAGA-3';

GCAGUUACCAGUGCCAAUA-3';

ErbB2-siRNA-1:

ErbB2-siRNA-2:

5'5'-

CAGAAUGGCUCAGUGACCU-3'.

2.2 Constructs and stable transfectants
For myc-His-tagged constructs, hRNase5 complementary DNA was subcloned
into a pcDNA6/myc-His-A vector (Invitrogen). For GST-tagged constructs, bRNaseA
and hRNase5 complementary DNAs were subcloned into a pGEX-6P-1 vector (GE
Healthcare). The myc-GST-tagged hRNase5 was constructed by PCR from mycHis-tagged hRNase5 with a C-terminal myc tag, and subcloned into a pGEX-6P-1
vector. For HeLa stable transfectants, bRNaseA and hRNase5 complementary
DNAs were subcloned into a modified pCDH-CMV-MCS-EF1-Puro vector (CD510B1, System Biosciences) containing a C-terminal Flag tag. Single-point mutants were
generated by site-directed mutagenesis. For AsPC-1-hRNase5 stable transfectants,
hRNase5 was subcloned into a pCDH-CMV-MCS-EF1-Puro vector. All stable
transfectants were established by lentivirus infection and selected with puromycin.
DyLight 594-bRNaseA was generated via fluorescent labeling of bRNaseA
recombinant proteins with DyLight 594 dye.

2.3 Cell culture
Cells were maintained in Dulbecco’s modified Eagle’s medium (DMEM)/F12 or
RPMI 1640 medium (for pancreatic cancer cell lines) supplemented with 10% fetal
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bovine serum and antibiotics. Pancreatic cancer cell lines were kindly provided by
Dr. Craig Logsdon (SW1990, SU.86.86) and Dr. Paul Chiao (CFPAC-1) at MD
Anderson Cancer Center. In this series of experiments, cells were treated with
bRNaseA and hRNase5 under serum-starved conditions for 24 h.

2.4 Cell lysis, Western blot, and immunoprecipitation
Cells were lysed in RIPA buffer (150 mM NaCl, 50 mM Tris [pH 7.5], 1%
Nonidet P-40, and protease inhibitor mixture) and by sonication. Total lysates were
collected after centrifugation at maximum speed and subjected to Western blot
analysis with the indicated antibodies. For immunoprecipitation, cells after bRNaseA
treatment were fixed with 1 mM dithiobis[succinimidylpropionate] (DSP, Thermo
Scientific) at room temperature for 30 min, and the cell lysates were then
immunoprecipitated with EGFR using an anti-EGFR and normal IgG antibodies as a
negative control, followed by Western blot analysis with the indicated antibodies.

2.5 Preparation of secreted proteins
Cells were maintained in a serum-starved medium for 24 h, and media
containing secreted proteins were collected. After filtration using 0.45 µm filters to
remove cell debris, media were concentrated at 5,000×g for 1 h by Amicon Ultra-15
Centrifugal Filter Units (UFC900324, Millipore) to a desired volume of secreted
proteins.

2.6 RNase activity detection assay
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RNase activity was detected using Ambion® RNaseAlert® Lab Test kit
(Invitrogen) with a slight modification. In brief, 5 µl of 10× RNaseAlert buffer was
added to one tube of fluorescent substrate, and 45 µl of the test sample was then
added to the tube. The mixture was sequentially pipetted into a well of a 96-well
plate, and monitored at 37°C to collect real-time fluorescence data at 5 min intervals
for the indicated time period using a BioTek Synergy™ Neo multi-mode reader.

2.7 Confocal microscopy
Confocal microscopy was performed as standard procedures described
previously (Wang et al., 2010c). Cells were fixed in 4% paraformaldehyde for 15
min, permeabilized with 0.5% Triton X-100 for 15 min, and blocked with 5% bovine
serum albumin for 1 h. After the incubation with primary antibodies overnight at 4°C,
cells were then further incubated with the appropriate secondary antibodies tagged
with fluorescein isothiocyanate, Texas red, or Alexa 647 (Molecular Probes) for 1 h
at room temperature. Nuclei were stained with DAPI contained in the mounting
reagent (Invitrogen). Confocal fluorescence images were captured using a Zeiss
LSM 710 laser microscope. Three-dimensional image was performed by Imaris
software (Bitplane). In all cases, optical sections through the middle planes of the
nuclei as determined using nuclear counterstaining were obtained.

2.8 Duolink® in situ proximity ligation assay (PLA)
Cells were fixed with 4% paraformaldehyde for 15 min, permeabilized with 0.5%
Triton X-100 for 15 min, and blocked with 5% bovine serum albumin. Cells were
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then incubated with mouse anti-EGFR antibody (1:2,000; Thermo Scientific) and
rabbit anti-bRNaeseA (1:400; Abcam) or anti-flag antibody (1:200; Cell Signaling)
for 30 min. The fluorescence signals were detected by the Duolink® in situ PLA
probe (Axxora) according to the manufacturer’s instructions and visualized by using
a Zeiss LSM 710 laser microscope.

2.9 Cell migration and invasion assays
Cell migration and invasion were performed using BioCoatTM Control Cell
Culture Insertsin and BioCoatTM Growth Factor Reduced Matrigel Invasion
Chambers (BD Biosciences), respectively. Culture medium containing 10% fetal
bovine serum as a chemoattractant was added to the plate and cells (2.5×104
cells/24-well chamber) in serum-free culture medium with the indicated treatments
were added to the chamber. The chamber was then incubated at 37°C for 24 h (for
HeLa cells) or 72 h (for AsPC-1 stable transfectants) to allow cells to penetrate an 8
µm pore size, uncoated membrane or a Matrigel-coated membrane. Cells remained
on the upper surface of the membrane were removed with a cotton swab, and those
on the underside of the membrane were fixed with 4% paraformaldehyde, stained
with 0.5% crystal violet, and microscopically counted from three random fields of
each membrane. The average cell number per field for triplicate membranes was
used to calculate the mean with SD. The values of cell migration and invasion are
shown as number of migrated cells and invaded cells per field, respectively. The
relative fold at empty vector without treatment or the first bar was defined as 1.
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2.10 Detection of ligands-EGFR binding affinity by ELISA
ELISA 96-well plates were captured with 3 µg/ml anti-EGFR antibody (Abcam)
in 0.2 M sodium phosphate buffer (pH 6.5) at 100 µl/well overnight at room
temperature. The plates were then rinsed three times with phosphate-buffered
saline with 0.05% Tween-20 (PBST) and blocked with 200 µl/well of 1% BSA
solution containing 0.05% Tween-20 at 37°C for 2 h. After rinsing three times with
PBST, 100 µl/well of A431-RIPA lysates or RIPA buffer only as a negative control
were added and incubated at 37°C for 1.5 h. The plates were then washed with 400
µl/well of 1M sucrose three times, shaking 1 min per time, followed by addition of
recombinant hRNase5, bRNaseA, or human biotin-EGF at a series of diluted
concentrations in RIPA buffer. After incubation at 37°C for 1.5 h, wells were washed
with 400 µl/well of 1M sucrose three times, shaking 1 min per time, and 100 µl/well
of biotin-conjugated detection antibodies in blocking buffer was added for incubation
at 37°C for 1 h. The plated were washed with 1M sucrose for three more times with
shaking, and 100 µl/well of streptavidin-conjugated HRP (1:2,000 in blocking buffer)
was added and incubated for 30 min at room temperature. The wells were washed
again with 1M sucrose three times with shaking, and 100 µl/well of TMB as a
peroxidase substrate were added and incubated for 30 min at room temperature.
The reaction was terminated by addition of 50 µl/well of stop solution. The optical
density was determined at 450 nm, corrected by subtraction of readings at 570 nm,
using a BioTek Synergy™ Neo multi-mode reader. The dissociation constant (KD)
and Bmax were estimated by the above binding data and then transformed to
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create a Scatchard plot with GraphPad Prism program (version 6; Prism Software
Inc., San Diego, USA).

2.11 Patient plasma samples
Total 40 patient plasma samples, collected as per protocols LAB01-526,
LAB10-0434 (TexGen biorepository), and LAB05-0131, were obtained from 30
patients with pancreatic adenocarcinoma, who were untreated previously
(cancer/case group: 10 males and 20 females; mean age, 58.8 years; range, 37-77
years) and 10 plasma samples from screening patients who do not have cancer
(normal/control group: 3 males and 7 females; mean age, 51.0 years; range, 32-54
years). Each patient provided informed consent at the time of plasma withdrawal.

2.12 Tissue microarray
Tissue microarray of 119 cases in pancreatic cancer were analyzed by
immunohistochemistry staining using anti-phospho-EGFR-Tyr1068 (1:50, 3777, Cell
Signaling) and anti-hRNase5 (1:50, AF265, R&D Systems) antibodies.
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Chapter 3
Bovine RNase A exhibits
an EGFR ligand-like function
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Background and Rationale
Elevated levels of ribonuclease (RNase) have been reported years ago in the
serum of pancreatic cancer patients (Reddi & Holland, 1976; Shimoyama et al.,
1996; Warshaw et al., 1980) and proposed to serve as a diagnostic marker for
pancreatic cancer (Misek et al., 2007; Zhao et al., 1998). Human RNase 5 (also
named angiogenin), which promotes malignancy through angiogenesis, was
speculated to have an unidentified cell surface receptor (Hu et al., 1997). Bovine
pancreatic RNase A (hereinafter referred to as bRNaseA), the first enzyme
sequenced as a classic model system for protein structure and enzymatic function
(Raines, 1998), is a secreted endoribonuclease commonly used in research to
remove RNAs (Benito et al., 2008; Cuchillo et al., 2011; Findlay et al., 1961;
Marshall et al., 2008). One of the most well-characterized cell surface receptors, the
epidermal growth factor receptor tyrosine kinase (EGFR-RTK), is a target of many
cancer therapies. RNases and RTKs from two unrelated superfamilies are
associated with distinct functions but they may share a common role in signal
transduction as extracellular RNAs (eRNAs) have recently been discovered to act
as signaling molecules and even serve as therapeutic biomarkers (Dinger et al.,
2008; Fischer et al., 2013).
In an attempt to study how eRNAs might affect cell signaling, which is not fully
understood, we unexpectedly discovered that bovine RNase A and its human
equivalent, RNase 5/angiogenin, function as unique EGFR ligands and that serum
RNase 5 may contribute to resistance to EGFR targeted therapy, cetuximab.
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Results
3.1 Bovine RNase A promotes oncogenic transformed phenotypes
To study how eRNAs affect cellular processes and determine their potential
clinical significance, we designed a pilot test by treating cells with a recombinant
bRNaseA protein to broadly degrade eRNAs. The catalytic activity of bRNaseA was
validated by RNase activity detection assay (Figure 3-1A) and sucrose gradient
fractionation using p68 RNA helicase as a positive control (Sytnikova et al., 2011)
(Figure 3-1B). Interestingly, we found that bRNaseA triggered oncogenic
transformed phenotypes. Specifically, bRNaseA induced epithelial-mesenchymal
transition (EMT)-like morphological changes in different cancer types (Figure 3-2)
accompanied by changes in EMT markers, including decreased expression of Ecadherin and enhanced expression of mesenchymal markers Vimentin, ZEB-1, Slug,
and Snail (Figure 3-3). Cells treated with bRNaseA also showed enhanced cell
mobility (Figure 3-4) and cell migration and invasion in a dose-dependent manner
(Figure 3-5), except for cell growth (Figure 3-6). These results suggest that
bRNaseA induces EMT.

3.2 Extracellular RNA is not involved in bovine RNase A-triggered EMT
To further determine whether eRNAs are involved in bRNaseA-triggered EMT,
we tested if the catalytic enzyme-deficient mutant of bRNaseA can still induce EMT.
To this end, we generated a GST-tagged wild-type bRNaseA (GST-bRNaseA-WT)
and a catalytic-deficient mutant (GST-bRNaseA-H119A) bearing a single mutation
at His119 (Zegers et al., 1994) (Figure 3-7A). Surprisingly, a comparison between
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Figure 3-1.
1. bRNaseA harbors endoribonuclease enzyme activity.
(A) Detection of bRNaseA enzyme activity, at 50 pg/ml, using an RNaseAlert® Lab
Test kit monitored by a real
real-time fluorometer. (B)) Sedimentation pattern of p68 RNA
helicase, a RNA binding protein as a p
positive
ositive control, through linear 10–40%
10
(topbottom) sucrose gradients.

31

EMT-like
like phenotypes.
Figure 3-2. Treatment of bRNaseA triggers EMT
(A and C) Cell
ell morphological change of four pancreatic cell lines, and a lung (H226)
and ovarian ( SkOV3) cancer cell line treated with bRNaseA for 2 days. (B)
( Cell
morphological change of HeLa cells treated with bRNaseA in a dose-dependent
dose
manner for 1 day.
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Figure 3-3. Treatment of bRNaseA modulates molecular EMT makers.
AsPC-1 (A), Panc-1 (B),
), and HeLa cells ((C)) were treated with bRNaseA at different
time points and lysates were subjected to Western blot analysis with the indicated
antibodies (EMT markers).
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wound-healing
healing assay.
Figure 3-4. bRNaseA enhances cell mobility in a wound
The distance of the wound gaps at the indicated time points determined using the
ImageJ software program (version 1.38x; National Institutes of Health) and
normalized against the width at time 0 was plotted diagrammatically as shown in the
lower panel. Error
or bars represent SD from three independent experiments.
Statistical analysis was performed by Student’s t test. *, P < 0.05; **, P < 0.01.
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Figure 3-5. bRNaseA
RNaseA triggers cell migration and invasion in a dose-dependent
dose
manner.
matrigel-coated
coated invasion
Mgration assay in transwells and invasion assay in matrigel
chambers of HeLa cells. Top, representative images shown. Bottom, quantification
of cell migration and invasion
invasion. Error bars represent SD. n = 3. Statistical analysis
was performed by Student’s t test. *, P < 0.05; **, P < 0.01.
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Figure 3-6. The effect of bRNaseA on cell proliferation.
Cell numbers were measured by a Coulter® Particle Counter (Beckman Coulter) in
different cell lines. Error bars represent SD. n = 3.
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Figure 3-7. Extracellular RNA is not involved in bRNaseA
bRNaseA-triggered
triggered EMT.
(A)) Coomassie blue staining of bacterial
bacterial-purified GST-tagged
tagged plasmids, including
GST-bRNaseA-WT
WT and GST
GST-bRNaseA-H119A,
H119A, and increasing amounts of
recombinant bRNaseA.
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cells treated with GST-bRNaseA-WT and those treated with GST-bRNaseA-H119A
revealed similar morphological changes (Figure 3-7B) and expression levels of
ZEB-1 (Figure 3-7C), suggesting that the catalytic activity of bRNaseA is not
required. The enzymatic activity of GST-bRNaseA-H119A was abolished as
indicated by RNase activity detection assay (Figure 3-7D). Together, these data
indicate that bRNaseA itself but not the degradation of eRNAs induces EMT (see
more details in Chapter 5).

3.3 Bovine RNase A triggers signaling cascades of tyrosine-phosphorylation
Since bRNaseA can enter cells (Chao & Raines, 2011), we suspected that the
internalized bRNaseA may play a role in EMT induction. Indeed, increased uptake
of bRNaseA (signified by red color) was readily detectable without significant
changes in the intracellular RNA levels as indicated by SYTO green fluorescence
staining (Figure 3-8).
Tyrosine kinase cascades have been shown to associate with EMT (Hardy et
al., 2010; Huber et al., 2005), and thus we asked whether bRNaseA might induce
EMT by activating the tyrosine kinase cascades. To this end, we examined the
phospho-tyrosine (p-Tyr) profile in the presence of bRNaseA treatment in cellular
lysates by blotting with a p-Tyr antibody. Interestingly, we found that bRNaseA
triggered signaling cascades of tyrosine phosphorylation in multiple types of cancer
cells (Figure 3-9). Notably, the p-Tyr content corresponding to the RTK-equivalent
molecular weight was substantially increased by bRNaseA treatment (170 to 200kDa).
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Figure 3-7.
7. Extracellular RNA is not involved in bRNaseA
bRNaseA-triggered
triggered EMT.
(B) Cell morphologicall change of HeLa cells treated with GST-vector,
GST
GSTbRNaseA-WT, and GST-bRNaseA
bRNaseA-H119A for 3 days. (C)) Cell lysates from (B) were
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subjected to Western blot analysis with the antibody against the EMT marker, ZEB1. Tubulin served as loading control. (D) Detection of RNase enzyme activity in
GST-vector, GST-bRNaseA-WT, and GST-bRNaseA-H119A using an RNaseAlert®
Lab Test kit monitored by a real-time fluorimeter.
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8. bRNaseA internalizes into cells with no interference of intracellular
Figure 3-8.
RNA level.
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Confocal microscopy of RNA level staining with SYTO® RNASelect™ greenfluorescent cell stain and bRNaseA using an anti-bRNaseA antibody (red signals)
for a 30-min treatment of bRNaseA in human cervical HeLa (A), pancreatic cancer
AsPC-1 (B), and bovine kidney MDBK (C) cells. Nuclei were stained with DAPI. Bar,
5 µm.
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9. bRNaseA triggers signaling cascades of tyrosine
tyrosine-phosphorylation.
phosphorylation.
Figure 3-9.
(A) HeLa, (B) pancreatic
pancreatic, (C) breast,
ast, ovarian, lung cancer cells as well as (D)
bovine kidney cells were treated with or without bRNaseA, and lysates were
subjected to Western blot analysis with a phospho
phospho-tyrosine (p-Tyr)
Tyr) antibody.
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3.4 EGFR-RTK is the primary target of bovine RNase A
We then performed a non-biased antibody array for human phospho-RTKs to
determine which RTK(s) might be the target(s) of bRNaseA. Among 49 RTKs in the
array, only EGFR and ErbB2 had increased phosphorylation after bRNaseA
treatment in both cervical (HeLa) and pancreatic (AsPC-1) cancer cells (Figure 310). We further validated the results using the phospho-tyrosine antibodies specific
for EGFR and ErbB2 and found that most tyrosine phosphorylation peaked at 5 min
after bRNaseA treatment (Figure 3-11), a phenomenon similar to EGFR ligand
stimulation (Avraham & Yarden, 2011). To further address which of these two RTKs
is required for bRNaseA-dependent tyrosine phosphorylation, we knocked down
EGFR and ErbB2 by small interfering RNAs (siRNAs). Silencing EGFR attenuated
ErbB2 tyrosine phosphorylation without affecting ErbB2 expression, but not vice
versa (Figure 3-12A). We also observed similar results in EGFR-knockdown stable
cells expressing small hairpin RNA (shRNA) targeting EGFR (Figure 3-12B).
Together, these results suggest that ErbB2 tyrosine phosphorylation induced by
bRNaseA is dependent on EGFR. Interestingly, in MDA-MB-453 breast cancer cells
that do not express endogenous EGFR, bRNaseA treatment had no effect on pantyrosine phosphorylation (Figure 3-12C), which strongly suggests that EGFR, but
not ErbB2, is the predominant target of bRNaseA.
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Figure 3-10. EGFR and ErbB2 show increased phosphorylation after bRNaseA
treatment in human phospho
phospho-RTK antibody array.
HeLa and AsPC-1
1 cells were treated with or without bRNase A, and lysates were
subjected to human phospho
phospho-RTK antibody array analysis.
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ErbB2.
Figure 3-11.. bRNaseA treatment activates EGFR and ErbB2
HeLa (A) and AsPC-1 (B
B)) cells were treated with bRNaseA at different time points,
and lysates were subjected to Western blot analysis with the indicated antibodies.
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Figure 3-12.. ErbB2 tyrosine phosphorylation induced by bRNaseA is EGFR
kinase-dependent.
(A) Western blot analysis of lysates from HeLa cells transfected with the individual
siRNAs against EGFR and ErbB2 in the presence or absence of bRNaseA.
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Figure 3-12.. ErbB2 tyrosine phosphorylation induced by bRNaseA is EGFR
kinase-dependent.
EGFR-deficient
deficient stable transfectants
(B) Western blot analysiss of lysates of HeLa EGFR
(EGFR-A and EGFR-B)
B) in the presence or absence of bRNaseA. ((C
C) MDA-MB-453
and SKBR3 cells were treated with or without bRNaseA, and lysates
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3.5 Bovine RNase A activates EGFR downstream signaling pathways
To further pursue whether bRNaseA activates the downstream signaling
cascades of EGFR, another antibody array for human phospho-kinases was
performed. The results showed that six serine and threonine signaling pathways,
including p38α, ERK1/2, Gsk-3α/β, Akt, CREB, and RSK1/2/3, were commonly
phosphorylated in two cells after bRNaseA treatment (Figure 3-13), in which some
candidates, such as ERK1/2 and Akt pathways, were confirmed using the indicated
antibodies (Figure 3-14). Pretreating these cells with small-molecular tyrosinekinase inhibitors (TKIs) targeting EGFR (gefitinib and AG1478) blocked the
bRNaseA-triggered EGFR, and subsequently Akt and ERK, activation (Figure 3-15).
These results indicate that bRNaseA triggers EGFR-downstream signaling in an
EGFR kinase-dependent manner.

3.6 Bovine RNase A associates with EGFR in vivo and in vitro
Since bRNaseA stimulates tyrosine phosphorylation of EGFR and its
downstream signaling, we asked whether bRNaseA functions as an EGFR ligand.
To this end, we first validated the association between EGFR and bRNaseA by
multiple methods, including in vivo co-immunoprecipitation, in vitro binding assay,
confocal microscopy, and Duolink in situ proximity ligation assay (PLA). bRNaseA
co-immunoprecipitated with EGFR using an anti-EGFR antibody in vivo (Figure 316A), and the interaction was primarily through the extracellular domain (ECD) of
EGFR (Figure 3-16B). In addition, bRNaseA interacted with the N-terminal EGFR
recombinant protein (N-EGFR-Fc) that contained only the extracellular ligand-
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Figure 3-13. bRNaseA activates EGFR downstream signaling pathways in a
human phospho-kinase
kinase antibody array.
HeLa and AsPC-1
1 cells were treated with or without bRNase A, and lysates were
subjected to human phospho
phospho-kinase antibody array analysis.
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14. bRNaseA treatment activates ERK and Akt.
Figure 3-14.
HeLa (A) and AsPC-1 (B
B)) cells were treated with bRNaseA at different time points,
and lysates were subjected to Western blot analysis with the indicated antibodies.
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Figure 3-15. EGFR-TKIs
TKIs blocks bRNaseA
bRNaseA-triggered
triggered EGFR signaling.
signaling
HeLa cells were pretreated with EGFR
EGFR-TKIs
TKIs (gefitinib and AG1478), followed by
bRNaseA treatment, and lysates were subjected to Western blot analysis with the
indicated antibodies.
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Figure 3-16. bRNaseA
RNaseA associates with EGFR
EGFR.
(A)) HeLa cells underwent immuneprecipitation with antibodies targeting EGFR or
normal IgG. Precipitates were analyzed by Western blot the indicated antibodies.
The right panel
anel shows the input lysates. ((B) In vivo binding assay of bRNaseA in
293T cells transfected with myc
myc-His-tagged
tagged EGFR containing full-length
full
(FL),
extracellular domain (ECD), and intracellular domain (ICD) plasmids, pulled down
using His beads.
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binding domain in vitro (Figure 3-16C). Consistent with the biochemical studies, we
observed

co-localization

of

EGFR

and

bRNaseA

using

confocal

immunofluorescence assay as indicated by yellow signals in the merged image
(Figure 3-17A), which was further validated by examining sequential photosections
of a cell in multiple layers in three-dimensions (Figure 3-17B). This EGFR/bRNaseA
association (indicated by yellow merged signals) was also detected by a nonantibody-based approach using bRNaseA recombinant proteins labeled with
DyLight 594 dye that generated red fluorescence for confocal analysis (Figure 3-18).
In addition, a new and more sensitive Duolink in situ PLA technology, which utilizes
detectable DNA molecules amplified by binding of two protein-DNA conjugates in
close proximity (Fredriksson et al., 2002), demonstrated a number of interactions
between EGFR and bRNaseA (Figure 3-19). These results from these assays
support the bRNaseA/EGFR association both in vitro and in vivo.

3.7 Bovine RNase A acts as an EGFR ligand to convey intracellular EGFR
signaling
We further found that cetuximab, a monoclonal EGFR antibody that blocks
binding of ligands to EGFR, inhibited bRNaseA-induced activation of EGFR and its
downstream Akt signaling (Figure 3-20). Disrupting the interaction between the Nterminal ligand-binding domain of EGFR and bRNaseA by competition with an NEGFR-Fc recombinant protein or EGFR-ECD also decreased EGFR activation
triggered by bRNaseA (Figure 3-21). Collectively, the results suggest an
unrecognized role of bRNaseA as an EGFR ligand to convey EGFR signaling.
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Figure 3-16. bRNaseA associates with EGFR
EGFR.
(C) In vitro binding assay of bRNaseA and N
N-EGFR-Fc, an N-terminal EGFR
recombinant protein, pulled down using protein G beads. Normal IgG and BSA
served as negative controls.
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Figure

3-17.

bRNaseA

co
co-localizes

immunofluorescence assay
assay.
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with

EGFR

using

confocal

(A) Confocal microscopy of HeLa cells stained with DAPI (blue), anti-bRNaseA
(green), and anti-EGFR (red) antibodies. Boxed areas are shown in detail in the
insets. Bar, 5 µm. (B) A single HeLa cell was dissected into 32 focal sections with a
thickness of 0.5 µm each. The nucleus spanned between focal plans 04-12. Colocalization of EGFR and bRNaseA, as indicated by the yellow signals in the
merged images, is shown from plans 06-10 in the insets (white arrows). Boxed
areas are shown in detail in the insets. Bar, 5 µm.
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Figure 3-18. DyLight 594
594-labeled bRNaseA co-localizes
localizes with EGFR.
EGFR
(A)) Confocal microscopy of HeLa cells stained with DAPI (blue), DyLight 594594
labeled bRNaseA (red), and an anti-EGFR
EGFR antibody (green). Boxed areas are
shown in
n detail in the insets. Bar, 5 µm. (B) Intensity profile of two yellow signals
shown in Inset 1 of (A).
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Figure 3-19. bRNaseA interacts with EGFR using Duolink in situ PLA
technology.
Detection of EGFR and bRNaseA interaction by Duolink in situ PLA technology.
HeLa cells were stained with EGFR and bRNaseA antibodies. The number of
interactions per cell is shown on the right. Error bars represent SD. n = 3.
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Figure 3-20. Cetuximab attenuates bRNaseA
bRNaseA-induced
induced activation of EGFR and
its downstream Akt signaling.
HeLa cells were pretreated with cetuximab (10 µg/ml) at 4°C for 1 h, followed by
bRNaseA stimulation for 5 min, and lysates were subjected to Western blot analysis
with
ith the indicated antibodies.

60

Figure 3-21.. Blockage of the association between EGFR and bRNaseA inhibits
bRNaseA-induced
induced EGFR signaling.
(A)) HeLa cells were treated with bRNaseA pre
pre-incubated
incubated with or without N-EGFRN
Fc, as indicated, and lysates were subjected to Western blotting with the indicated
antibodies. (B)) HeLa cells transfected with the extracellular domain of EGFR
(EGFR-ECD)
ECD) were treated with bRNaseA treatment, and lysates were subjected to
Western blotting with the indicated antibodies.
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Chapter 4
Human RNase 5 serves
as an EGFR ligand

62

Background and Rationale
The human RNase A superfamily consists of 13 members and all are secretory
proteins (Cho et al., 2005). In addition to their catalytic activities against specific
RNAs, they possess a number of physiological functions, e.g., digestion of dietary
RNA (RNase 1), angiogenesis (RNase 5/angiogenin; hereinafter referred to as
hRNase5), and antiviral host defense (RNases 2, 3, 7) (Li & Hu, 2012; Rosenberg,
2008; Sorrentino, 2010). Among them, human pancreatic RNase 1 and hRNase5
are most evolutionarily closely related to bRNaseA (Peracaula et al., 2000;
Rosenberg, 2008). We next investigated whether the newly discovered function of
bRNaseA, which acts as an EGFR ligand and promotes transformed phenotypes,
also exists in human RNase A members.

Results
4.1 Human RNase 5 is predominantly secreted in pancreatic cancers
We examined the levels of secreted hRNase5 and RNase 1 in a panel of 10
pancreatic cancer cells and found all cell lines secreted hRNase5 whereas only one
cell line (Capan-1) secreted RNase 1 (Figure 4-1), suggesting that hRNase5 is the
RNase predominantly expressed in pancreatic cancers. Furthermore, we analyzed
the correlation of EGFR with ANG (gene encoding hRNase5 protein) and RNASE1
in pancreatic ductal adenocarcinoma using the cancer microarray database
ONCOMINE (Rhodes et al., 2004). EGFR correlated positively with ANG1 (P <
0.0001) (Figure 4-2) but not RNASE1.
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Figure 4-1. hRNase5 is secreted in a panel of 10 pancreatic cancer cells.
Analysis of the expression level of hRNase5 and RNase 1 proteins secreted in
pancreatic cancer cells.
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Figure 4-2. hRNase5 correlat
correlates positively with EGFR in pancreatic ductal
adenocarcinoma.
Heat map analysis of EGFR and hRNase5 in pancreatic ductal adenocarcinoma
(PDAC) via a cancer microarray database, ONCOMINE, plotted diagrammatically in
the lower panel. n = 87.
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4.2 Human RNase 5 functions as an EGFR ligand to activate EGFR signaling
We then investigated whether hRNase5 also functions as an EGFR ligand.
Indeed, similar to bRNaseA, hRNase5 bound to the N-terminal domain of EGFR
directly (Figure 4-3A), which was attenuated by pretreatment of cetuximab (Figure
4-3B, lane 3 vs. lane 4). In addition, hRNase5 also activated EGFR and its
downstream targets in a dose-dependent manner (Figure 4-4). These hRNase5mediated EGFR activations were blocked by pretreatment of cetuximab (Figure 4-5)
and EGFR-TKIs (Figure 4-6), further supporting that like bRNaseA, hRNase5 also
functions as an EGFR ligand to convey intracellular signaling by binding to the
extracellular ligand-binding domain of EGFR.

4.3 Human RNase 5 triggers cell migration and invasion through the binding
to and activating EGFR
To determine whether EGFR is required for hRNase5-triggered oncogenic
functions in pancreatic cancers, we generated AsPC-1 stable transfectants that
express hRNase5 (designated as AsPC-1-hRNase5; Figures 4-7A and 4-7B) at a
level comparable to CFPAC-1 cells that express high levels of hRNase5 (Figure 47C) and performed cell migration and invasion assays. Compared with vector
control, hRNase5-expressing stable cells exhibited enhanced cell migration and
invasion (Figures 4-8A and 4-8B), but these effects were significantly repressed by
pretreating cells with cetuximab, EGFR-TKIs, or hRNase5 neutralizing antibody
(ANG Ab). These results support the notion that hRNase5 triggers pancreatic
cancer cell migration and invasion via binding to and activating EGFR.
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Figure 4-3. Cetuximab attenuates in vitro interaction between hRNase5 and
EGFR.
tagged plasmid expressing hRNase5 (GST(GST
(A) Left: in vitro binding assay of a GST-tagged
hRNase5) and N-EGFR-Fc,
Fc, pulled down using protein G beads. An
A empty vector
(GST) alone is a negative control. (B) In vitro binding assay of GST-hRNase5
GST
and
N-EGFR-Fc,
Fc, which was pre
pre-incubated
incubated with cetuximab. An asterisk represents
binding and expression of GST
GST-hRNase5.
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Figure 4-4.. hRNase5 treatment activates EGFR and the downstream signaling
pathways.
HeLa cells were treated with increasing concentrations of hRNase5 for 5 min and
lysates were subjected to Western blotting with the indicated antibodies.
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induced activation of EGFR and its
Figure 4-5. Cetuximab attenuates hRNase5-induced
downstream Akt signaling.
HeLa cells were pretreated with cetuximab (10 µg/ml) at 4°C for 1 h, followed by
hRNase5 stimulation for 5 min, and lysates were subjected to Western blot analysis
with
ith the indicated antibodies.
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mediated EGFR
Figure 4-6.. Pretreatment of EGFR-TKIs inhibits hRNase5-mediated
activation.
), and HeLa ((C)) cells were pretreated with EGFR-TKIs
EGFR
AsPC-1 (A), Panc-1 (B),
(erlotinib or gefitinib), followed by hRNase5 treatment for 5 min, and lysates were
subjected to Western blotting with the indicated antibodies.
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AsPC-1-hRNase5
hRNase5 stable transfectants are
Figure 4-7. The levels of hRNase5 in AsPC
comparable to those
hose in highly
highly-expressed cells.
(A)) Western blot analysis of secreted proteins in AsPC-1
1 stable transfectants
expressing hRNase5 (AsPC
(AsPC-1-hRNase5)
hRNase5) and empty vector (AsPC-1-vector).
(AsPC
A
comparison of hRNase5 expression level in AsPC
AsPC-1-hRNase5
hRNase5 and AsPC-1-vector,
AsPC
to increasing amounts of recombinant hRNase5 proteins ((B)) and in other
oth pancreatic
cancer cell lines (C).
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Figure 4-8. hRNase5 triggers cell migration and invasion through the binding
to and activating EGFR.
(A)) Representative images of cell migration and invasion assays of AsPC-1
AsPC stable
transfectants expressing hRNase5 ttreated
reated with an EGFR antibody (cetuximab), an
EGFR-TKI
TKI (gefitinib), or hRNase5 neut
neutralization
ralization antibody (ANG Ab). (B)
(
Quantification of celll migration and invasion from (A
(A).
). Error bars represent SD. n = 3.
Statistical analysis was performed by Student’s t te
test.
st. **, P < 0.01; ***, P < 0.001.
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4.4 The expression level of human RNase 5 is significantly elevated in
pancreatic cancer patients
Decades ago, investigators reported that the activities of serum RNases (Reddi
& Holland, 1976; Warshaw et al., 1980), and later the expression of hRNase5
(Shimoyama et al., 1996) were elevated in pancreatic cancer patients and
suggested that RNases could serve as diagnostic markers in pancreatic cancer
progression (Misek et al., 2007; Zhao et al., 1998). We re-evalulated the
concentration of RNase 1 and hRNase5 in the plasma samples of pancreatic cancer
patients for comparison with non-cancer control group (Figure 4-9). Consistent with
the previous report (Shimoyama et al., 1996), a significant increase in plasma
hRNase5 was indeed detected in the cancer group (P = 0.014; Figure 4-9A)
whereas the mean concentrations of plasma RNase 1 between these two groups
were not significant (P = 0.83; Figure 4-9B).
Interestingly, there were no significant differences in traditional EGFR ligands,
EGF and TGF-α, between normal and pancreatic cancer patient samples (Figures
4-9C and 9D); their mean concentrations in patients were approximately 20,000-fold
lower than that of plasma hRNase5 (18.1 and 15.6 pg/ml vs. 458.8 ng/ml; Table 41).

73

Figure 4-9.. Human RNase 5 is elevated in plasma samples of pancreatic
cancer patients.
), human RNase 1 ((B), EGF (C), and TGF-α
α (D) in plasma
Analysis of hRNase5 (A),
samples of pancreatic cancer patients for comparison with non-cancer
cancer control group
by an enzyme-linked
linked immunosorbent assay (R&D Systems).
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1. Analysis of hRNase5, human RNase 1, EGF, and TGF-α
TGF in plasma
Table 4-1.
samples of pancreatic cancer patients for comparison with non-cancer
control group by ELISA.
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4.5 A physiological relevance between activated EGFR and human
uman RNase 5 in
pancreatic cancers
Importantly, human pancreatic tumor tissue microarrays showed that phosphophospho
EGFR-Y1068,
Y1068, which is indicative of EGFR activation, was positively correlated with
hRNase5 expression (P = 0.03; Figure 4-10),
), strongly suggesting a physiological
association between activated EGFR and hRNase5 in pancreatic cancers.

Figure 4-10. hRNase5 correlates positively with activated EGFR expression in
human pancreatic tissue microarrays
microarrays.
Pancreatic cancer tissue microarray analysis for the correlation between hRNase5
and phospho-EGFR-Y1068.
Y1068.
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Chapter 5
The EGFR ligand-like activity
of pancreatic RNase is
independent of its enzyme activity
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Background and Rationale
RNase is well known to associate with intrinsic catalytic enzyme activities to
degrade RNA (Cuchillo et al., 2011; Marshall et al., 2008); however, as previously
mentioned, bRNaseA induced EMT via a catalytic-independent pathway (Figure 37). Next, we asked whether hRNase5 and bRNaseA bind to EGFR and activate
EGFR signaling pathways, such as Akt and ERK, in a catalytic-independent
pathway.

Results
5.1 RNase enzyme activity is not required for tyrosine-phosphorylation
cascades triggered by GST-bRNaseA
In addition to an enzymatic activity-independent role of bRNaseA in EMT
process, the increased p-Tyr profile and EGFR activation were also observed in the
cells treated with enzyme-deficient GST-bRNaseA-H119A mutant, at a similar level
compared to that with GST-bRNaseA-WT (Figure 5-1), suggesting that bRNaseAtriggered tyrosine-phosphorylation cascades were independent of its catalytic
enzyme activity.

5.2 RNases activate and bind to EGFR independently of their catalytic enzyme
activities
Thus, we then asked whether the enzyme activities of bRNaseA and hRNase5
expressed in mammalian cells were also independent of EGFR binding in addition
to the activation. To this end, we generated wild-type and catalytic enzyme-deficient
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triggered tyrosine
tyrosine-phosphorylation
phosphorylation cascades and EGFR
Figure 5-1. bRNaseA-triggered
activation is independent of its catalytic enzyme activity.
HeLa cells were treated with PBS only, GST
GST-vector, GST-bRNaseA
bRNaseA-WT, or GSTbRNaseA-H119A
H119A for 5 min, and lysates were subjected to Western blot analysis
with the indicated antibodies.
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mutants of bRNaseA and hRNase5, either by transient transfection or stably
expression in HeLa cells. Media from HeLa cells transiently transfected with empty
vector or Flag-bRNaseA plasmids expressing wild-type (Flag-bRNaseA-WT) or
catalytic-deficient bRNaseA mutant (Flag-bRNaseA-H119A) were collected and
concentrated to evaluate the RNase activities. As shown in Figure 5-2A, RNase
activities were abolished in cells expressing the Flag-bRNaseA-H119A mutant but
not in those expressing Flag-bRNaseA-WT as indicated by the loss of fluorescence.
Western blot analysis demonstrated that their expression levels were not affected
(Figure 5-2B). We found that the secreted bRNaseA-H119A mutant lacking RNase
activity still activated EGFR and the downstream ERK and Akt pathways at levels
similar to bRNaseA-WT (Figure 5-2C). In addition, the lack of RNase activity in the
catalytic-deficient mutant did not affect its interaction with EGFR (Figure 5-2D), and
these results were validated in stable transfectants (Figure 5-3).
A similar experiment was performed to test the catalytic-deficient mutants of
hRNase5 (K40A and H114A; Figure 5-4A) with results indicating that hRNase5
triggered EGFR phosphorylation (Figure 5-4B) and interacted with EGFR (Figure 54C). Together, these findings indicate that human RNase 5 and bovine RNase A
bind to EGFR and activate EGFR signaling pathways, without requiring their
catalytic activities.
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Figure 5-2. bRNaseA activate
activates and binds to EGFR independently of their
catalytic activities.
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(A) Detection of RNase enzyme activity in concentrated culture media collected
from cells transfected with Flag-bRNaseA-WT, Flag-bRNaseA-H119A, or empty
vector, by using an RNaseAlert® Lab Test kit and monitored by a real-time
fluorimeter. (B) Western blot analysis of secreted proteins in the media from HeLa
cells expressing Flag-bRNaseA-WT, Flag-bRNaseA-H119A, or empty vector. The
relative density at Flag-bRNaseA-WT was defined as 1 using the imageJ software
program (version 1.38x; National Institutes of Health) to quantify the signals. (C)
Left: HeLa cells were treated with culture media containing secreted proteins, as
indicated in (B), for 5 min and lysates were subjected to Western blotting with the
indicated antibodies. Right: the quantified signal representing the fold of EGFR
phosphorylation against the amounts of the indicated secreted proteins. Error bars
represent SD. n = 3. Statistical analysis was performed by Student’s t test. NS, P >
0.05, not significant. (D) Detection of EGFR and bRNaseA interaction by Duolink in
situ PLA technology. HeLa cells were treated with the secreted proteins, as
indicated in (B), for 15 min, and fixed and stained with anti-EGFR and antibRNaseA antibodies. The number of interaction per cell normalized to the amount
of the secreted proteins is shown right. Error bars represent SD. n = 3. Statistical
analysis was performed by Student’s t test. NS, P > 0.05, not significant.
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Figure 5-3.. bRNaseA secreted in stable transfectants binds to EGFR
independently of its catalytic activity.
(A)) Detection of RNase enzyme activity in the concentrated media of HeLa stable
transfectants expressing Flag
Flag-bRNaseA-WT, Flag-bRNaseA-K41A,
K41A, Flag-bRNaseAFlag
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H119A, and empty vector, using an RNaseAlert® Lab Test kit monitored by a realtime fluorimeter. (B) Western blot analysis of secreted proteins in HeLa stable
transfectants expressing Flag-bRNaseA-WT, Flag-bRNaseA-K41A, Flag-bRNaseAH119A, and empty vector. The relative density at Flag-bRNaseA-WT was defined
as 1 using the imageJ software program (version 1.38x; National Institutes of Health)
to quantify the signals. (C) Detection of EGFR and bRNaseA interaction by Duolink
in situ PLA technology. HeLa cells were treated with secreted WT, K41A, or H119A
bRNaseA for 15 min as described in (B) and fixed and stained with anti-EGFR and
anti-Flag antibodies. The number of interaction per cell normalized to the amount of
the secreted proteins is shown on the right. Error bars represent SD. n = 3.
Statistical analysis was performed by Student’s t test. NS, P > 0.05, not significant.
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Figure 5-4. hRNase5 secreted in stable transfectants activates and binds to
EGFR independently of its catalytic activity.
(A)) Western blot analysis of hRNase5 in the culture media of HeLa stable
transfectants expressing Flag
Flag-hRNase5-WT, Flag-hRNase5-K40A,
K40A, Flag-hRNase5Flag
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H114A, or empty vector. The relative density at Flag-hRNase5-WT was defined as
1 using the ImageJ software program (version 1.38x; National Institutes of Health)
to quantify the signals. (B) Left: HeLa cells were treated with secreted WT, K40A, or
H114A hRNase5 as described in (A) for 5 min and lysates were subjected to
Western blot analysis with the indicated antibodies. Right: quantitation of the fold of
EGFR phosphorylation against the amount of the indicated secreted proteins. Error
bars represent SD. n = 2. Statistical analysis was performed by Student’s t test. NS,
P > 0.05, not significant. (E) Detection of EGFR and hRNase5 interaction by
Duolink in situ PLA technology. HeLa cells were treated with secreted WT, K40A, or
H114A hRNase5 for 15 min as described in (A) and fixed and stained with antiEGFR and anti-Flag antibodies. The number of interaction per cell normalized to the
amount of the secreted proteins is shown on the right. Error bars represent SD. n =
3.
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Chapter 6
Characterization of interaction
between EGFR and RNases
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Background and Rationale
The EGFR ligand-like activity of hRNase5 prompted us to ask whether
hRNase5 share sequence homology with traditional EGFR ligands, such as EGF
and heparin-binding EGF-like growth factor (HB-EGF).

Results
6.1 The C-terminal hRNase5 possesses highly and evolutionally conserved
residuals with those on EGF and HB-EGF
Primary sequence alignment showed that the C-terminal region (known for
EGFR binding in EGF and HB-EGF) of hRNase5, EGF, and HB-EGF are highly and
evolutionally conserved in different species (shown in red; Figure 6-1).

6.2 The C-terminal domain of hRNase5 (amino acid 74-123) is required for
EGFR binding
To further study whether the C-terminal region of hRNase5 plays a role in
binding to EGFR, we generated wild-type (WT), N- (∆N), and C-terminal deletion
(∆C) constructs of hRNase5 and in vitro binding assay was performed. Consistent
with the analysis in Figure 6-1, we did not detect any association with EGFR when
this C-terminal region (amino acid 74-123) was deleted from hRNase5 (Figures 62A and 6-2B), suggesting that this region is required for EGFR binding.
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Figure 6-1. Sequence alignment of RNase5 to known EGFR ligands (EGF and
HB-EGF) in different species
species.
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T-coffee sequence alignment (Notredame et al., 2000; Taly et al., 2011) of EGF,
HB-EGF, and RNase 5 between human, mouse, and horse. Regions in red indicate
high consistency, orange/yellow as an average consistency, and green/blue as the
lowest consistency. Asterisks represent 100% conservation in all sequences; colons
and dots represent partial sequence conservation.
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Figure 6-2. The C-terminal
terminal hRNase5 is required for EGFR binding.
(A) A schematic diagram showing wild
wild-type (WT), N- (∆N), and C-terminal
terminal deletion
(∆C)
C) constructs of hRNase5. The numbers represent amino acid residues. NLS,
nuclear localization signal. (B) In vitro binding assay of N-EGFR
EGFR-Fc with GSThRNase5 WT and two of its deletion mutants, GST-hRNase5
hRNase5 ∆N
∆ and GSThRNase5 ∆C,
C, pulled down using protein G beads.
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6.3 Gln93 and Tyr94 within C-terminal region of human RNase 5 are critical for
efficient binding to EGFR
To map the potential EGFR binding site(s) in hRNase5, we compared the Cterminal region between human EGF, hRNase5, and several hRNase5 homologues
and found that they are indeed highly conserved (Figures 6-3A and 6-3B).
We identified four conserved residues, including two Cys (C81 and C92), which
are generally crucial for protein structure, and Gln (Q93) and Tyr (Y94) that
correspond to the side chains in human EGF reported to bind to EGFR (Figure 6-4A)
(Li et al., 2005), and when mutated to alanine, their association with EGFR was
inhibited (Figure 6-4B), suggesting that they may play a role in binding of hRNase5
to EGFR.
The decrease binding of hRNase5-Q93A to EGFR was further validated in vivo
by incubating N-EGFR-Fc with the collected media containing secreted WT and
Q93A mutant of hRNase5 following transfection (Figures 6-5A and 6-5B).
Interestingly, Y94 hRNase5 mutant was not detected in the media after transfection
as the mutation may have affected its secretion (Figure 6-5B). Similarly, no
interaction was detectable between EGFR and hRNase5 containing the Cys
mutants to alanine, likely due to lack of protein secretion in the media (Figure 6-6).
Together, results from the in vitro assays suggest that Q93 and Y94 within Cterminal region of hRNase5 are required for efficient binding to EGFR.
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Figure 6-3. Sequence alignment of human RNase 5 to human EGF and several
RNase 5 homologues reveals a highly conserved C-terminus.
(A) T-coffee
coffee sequence alignment of human RNase 5 and human EGF.
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Figure 6-3. Sequence alignment of human RNase 5 to human EGF and several
RNase 5 homologues reveals a highly conserved C-terminus.
(B) T-coffee
coffee sequence alignment between different species of RNase 5, including
human, mouse, horse, and cow, with human EGF.
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Figure 6-4.. Gln93 and Tyr94 within the C
C-terminus
terminus of hRNase5 are required for
EGFR binding.
(A)) Sequence alignment of human RNase 5 and human EGF. Asterisks represent
100% conservation in all sequences; colons and dots represent p
partial
artial sequence
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conservation. (B) Top: in vitro binding assay of N-EGFR-Fc with myc-tagged
hRNase5 containing WT, C81A, C92A, Q93A, or Y94A mutant, pulled down using
protein G beads. The relative density at myc-GST-hRNase5-WT was defined as 1
using the ImageJ software program (version 1.38x; National Institutes of Health) to
quantify the signals. Bottom: the quantified signal representing the fold ratio of
hRNase5 bound to EGFR.
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Figure 6-5. The in vivo association of hRNase5 with EGFR is decreased while
Gln93 of hRNase5 is mutated.
(A)) Left: binding assay of N
N-EGFR-Fc
Fc with the collected media from 293T cells
transfected with WT and Q93A mutant, pulled down using protein G beads.
Quantified ratio of hRNase5 bound to EGFR is shown on the right. (B
B) Western blot
analysis of 293T
3T cells expressing myc
myc-His-hRNase5
hRNase5 WT, Q93A, Y94A, or empty
vector in the lysates and in culture media (secreted proteins).
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Figure 6-6.. hRNase5 plasmids containing the Cys mutants to alanine are not
secreted in the media.
(A)) Binding assay of N
N-EGFR-Fc
Fc with the collected media from 293T cells
transfected with myc-GST
GST-hRNase5-WT,
WT, the indicated Cys mutants, and empty
vector, pulled down using protein G beads. ((B)) Immunoblotting analysis of 293T
cells expressing WT, two of its point mutants, and empty vector within the lysates
and secreted proteins.
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6.4 The binding affinity of human RNase 5 toward EGFR is within the range of
known EGFR ligands with high binding affinity
Next, we measured its binding affinity of hRNase5 for EGFR for comparison
with EGF. Notably, the binding of hRNase5 to the N-terminal region of EGFR was
relatively low (Figure 6-7A; ~70% binding ratio at 143 nM) compared with that of
EGF (Figure 6-7B; ~100% binding ratio at 3.33 nM).
For a more quantitative analysis, we performed enzyme-linked immunosorbent
assay (ELISA) captured by an EGFR antibody with or without A431 cell lysates to
determine the individual dissociation constants (KD). The estimated KD of EGF
bound to EGFR was 1.87 nM (Figure 6-8A), which was consistent with published
values (Bjorkelund et al., 2011; Ozcan et al., 2006). Under the same ELISA
condition, the binding affinity (KD) of hRNase5 and bRNaseA for full-length EGFR
was 36.6 nM (Figure 6-8B) and 885.3 nM (Figure 6-8C) or about 20-fold and 473fold less than that of EGF, respectively.
It is worthwhile to mention that there are two classes of human EGFR ligands,
including those with high affinity with a KD ranging between 1-100 nM (e.g,. EGF;
HB-EGF) and those with low affinity with a KD greater than 100 nM (e.g.,
amphiregulin, KD = 350 nM; epigen, KD > 500 nM; murine epiregulin, KD = 2.8 µM)
(Sanders et al., 2013). Thus, the KD of hRNase5 falls within the range of high affinity
EGFR ligands.
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Figure 6-7. The
he binding of hRNase5 to the N
N-terminal
terminal region of EGFR is
determined by using a pull
pull-down assay.
(A and B) Left: in vitro binding assay of N-EGFR-Fc
Fc across a range of
concentrations of hRNase5 (A) or EGF (B), pulled down using protein G beads.
BSA served as a negative control. Right: Quantification of hRNase5 (A) or EGF (B)
bound to EGFR against the individua
individual input.
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Figure 6-8.. Binding affinity of EGF, hRNase5, and bRNaseA toward EGFR are
detected by ELISA with estimated KD values.
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Left: different concentrations of EGF (A), hRNase5 (B), and bRNaseA (C) were
added to an EGFR-captured ELISA plate, with or without A431 cell lysates. Dotted
line represents Bmax (maximum number of binding sites). Error bars represent SD.
n = 2. Right: data derived using Scatchard plot analysis to determine KD values for
interaction of EGFR with EGF, hRNase5, and bRNaseA.
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Chapter 7
Human RNase 5 contributes to
cetuximab resistance
in pancreatic cancer
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Background and Rationale
Cetuximab, a FDA approved anti-cancer drug that prevents EGFR from binding
to its activating ligands, was proposed as a treatment modality for pancreatic cancer
as EGFR signaling was recently identified to be essential for tumor initiation in
pancreatic ductal adenocarcinoma (Ardito et al., 2012; Navas et al., 2012). However,
clinical trials using cetuximab as adjuvant therapy with gemcitabine to treat
pancreatic cancer did not improve the overall survival (Fensterer et al., 2013; Philip
et al., 2010). We therefore asked whether hRNase5 plays a role in resistance to
cetuximab therapy.

Results
7.1 hRNase5 enhances resistance to cetuximab therapy in pancreatic cancer
Strikingly, we found that cetuximab-repressed cell migration and invasion of
AsPC-1 pancreatic cancer cells was significantly increased in response to hRNase5
treatment in a dose-dependent manner (Figures 7-1A and 7-1B). This suggests that
hRNase5 is associated with cetuximab resistance.

7.2 hRNase5-enhanced cell migration and invasion is neutralized by an antihRNase5 antibody
In contrast, addition of an anti-hRNase5 antibody neutralized the enhanced cell
migration and invasion (Figures 7-2A and 7-2B). Together, the elevated level of
serum hRNase5 observed in pancreatic cancer patients is likely sufficient to activate
EGFR, which may in turn contribute to malignancy and resistance to cetuximab.
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repressed cell migration and invasion is
i significantly
Figure 7-1. Cetuximab-repressed
derepressed by hRNase5 treatment in a dose-dependent
dependent manner.
manner
(A)) Representative images from cell migration and invasion assays of AsPC-1
AsPC cells
treated with or without cetuximab (10 µg/ml) and various concentrations
concentration of
hRNase5 (1, 3, 9 µg/ml).
g/ml). ((B)) Quantification of cell migration and invasion from (A).
(
Error bars represent SD. n = 3. Statistical analysis was performed by Student’s t
test. *, P < 0.05;
.05; **, P < 0.01; ***, P < 0.001.
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Figure 7-2. hRNase5-enhanced
enhanced cell migration and invasion is neutralized by
an anti-hRNase5
hRNase5 antibody.
(A)) Representative images from cell migration and invasion assays of AsPC-1
AsPC cells
treated with cetuximab
tuximab (10 µg/ml), hRNase5 (2 µg/ml),, and ANG neutralization Ab
(5 µg/ml), as indicated. ((B)) Quantification of cell migration and invasion from (A).
(
Error bars represent SD. n = 3. Statistical analysis was performed by Student’s t
test. **, P < 0.01; ***, P < 0.001.
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Chapter 8
Discussion and Future work
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Our study has identified bovine RNase A and its human homologue RNase 5
can serve as specific ligands to activate surface EGFR to initiate its downstream
signaling network (Figure 8-1). It brings up one fundamental question that how
these secretory ribonucleases can bind to the extracellular domain of EGFR in a
specific manner. In our results, ribonuclease binding to EGFR can be impaired by
C225 pretreatment, which suggests that ribonuclease binding region on EGFR
extracellular domain could be very close to those bound by EGF. It is plausible that
ribonuclease may exert certain structural similarity to EGF-like ligands, or
ribonuclease could possess distinct and unknown conformation to be associated
with EGFR as a complex. Both secondary and tertiary structure of ribonucleases
and EGFR canonical ligands are well studied and established. Based on current
knowledge about these two protein families, they are very different from each other
in terms of disulfide bond linkage and crystal structure. Interestingly, there exist
certain homology between human RNase 5 and human EGF in their primary
sequence. Among these conserved residues, Q93 and Y94 residues of human
RNase 5 are corresponding cognates to Q43 and Y44 of EGF protein, where Q43
and Y44 have been shown to locate on the interface of EGF during its binding to
EGFR although both residues are not essential to this interaction. Either Q93A or
Y94A mutation can significantly decrease human RNase 5 binding to EGFR protein
in vitro. It provides certain evidence to support that the binding region of human
RNase 5 with EGFR may be similar to EGF with EGFR in a certain degree. To draw
a more delicate and authentic picture of the complex formed by RNase and EGFR,
we need to apply X-ray crystallography and NMR spectrometry to analyze their co-
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Figure 8-1. A proposed model for mammalian secretory ribonucleases to
provoke EGFR signaling pathways and EMT
EMT-like
like phenotypes in human
pancreatic cancer.
Bovine RNase A (bRNaseA) and its human homologue RNase 5 (hRNase5) act as
EGFR ligands to directly activate cell surface EGFR/EGFR
/EGFR homo-dimer
homo
or
EGFR/ErbB2 hetero-dimer,
dimer, initiate its downstream signaling network,
network leading to cell
migration, invasion, and EMT
EMT-like phenotypes. This ligand-like
like activity,
activity which is
independent of RNases’ enzymatic activity
activity,, contributes to tumor progression and
C225 resistance in pancreatic cancer cells
cells.
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crystal structure and compared them with well-resolved structure composed of
EGFR and conventional ligands like EGF or HB-EGF. More efforts to explore the
structural insights of RNase-EGFR complex will provide novel viewpoints of EGFR
activation because they may interact with each other through a way quite distinct
from EGF-EGFR complex.

Our research has revealed the first example that human RNase 5 can act as
EGFR ligand independently of its enzyme activity. It is reasonable to speculate that
other members of RNase A family may have similar function to serve as ligands for
other receptors, in addition to their conventional roles as ribonucleases and
participants in immunity. Notably, among the 13 members of RNase A family,
RNase 9-13 are known to lose enzymatic activity as non-canonical ribonucleases.
It would be interesting to test if any of them can be a cognate ligand to certain
membrane receptor as well. A more systematic primary sequence alignment
between RNase A family members and protein growth factors can be conducted to
see if there exist any evolutional conservation among them. Moreover, ectopic
expression of individual ribonuclease to stimulate recipient cells through conditioned
medium combined with analysis through kinase antibody arrays will help to
elucidate a potential role of other ribonuclease as a novel ligand to a known
receptor. Future studies on this point of view may define certain ribonucleases as
specific ligands to receptors to initiate cellular signaling pathways, and it can
provide an explanation and biological role for those existing ribonucleases which
lose their catalytic activities during evolution. On the other hand, it provides more
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opportunities to find out new ligands for membrane receptors especially those
without known ligands. Since ErbB2 is an orphan receptor without any known ligand
to date, this approach may help to identify a first ligand of ErbB2 in the future.

Previous studies have indicated human RNase 5 can bind to a 170-kDa
membrane receptor of endothelial cells to trigger intracellular signaling and promote
angiogenesis. Of note, EGFR is a 170-kDa receptor tyrosine kinase and in our
study it is identified as the primary receptor of tumor cells to be associated with
ribonuclease and initiate downstream signaling including AKT and ERK activation
upon ribonuclease stimulation. Our work may provide an adequate answer to a
long- term issue for years. According to previous reports, tumor-associated
endothelial cells express higher level of EGFR and the EGFR signaling is required
for their proliferation and angiogenic function. Since previously the unknown 170kDa membrane receptor was identified from endothelial cells, it would be worthwhile
to investigate if human RNase 5 can bind to EGFR of tumor-associated endothelial
cells, like we have observed with tumor cells. The experimental results will help to
address if our current model can be applied to endothelial cells through a paracrine
manner, since we have demonstrated that secreted ribonuclease can activate
EGFR signaling in tumor cells through an autocrine mechanism. The same
possibility also exist between tumor and stromal cells, because in pancreatic cancer
the stromal cells play a crucial role for cancer aggressiveness and chemoresistance,
and through a paracrine pathway that ribonuclease may also stimulate EGFR
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signaling in tumor-associated stromal cells to aggravate pancreatic cancer
tumorigenesis.

We recently demonstrated that human RNase 5 can activate EGFR signaling in
pancreatic cancer cells. In addition, the EGFR activation is essential to human
RNase 5-provoked cell migration and invasion. Animal studies including pancreatic
cancer orthotopic model or transgenic mice with KRASG12D and p53 knockout can
be conducted in the future to see if human RNase 5 can contribute to pancreatic
cancer occurrence and progression. Those mouse models will help us to investigate
if RNase 5 level is elevated in the initiation or early phase of pancreatic cancer
progression. Accordingly, human RNase 5 level in patient serum is significantly
elevated compared to normal donors, and it may confer tumor cells more insensitive
to C225 treatment but more sensitive to TKI therapy. A proposed combinational
therapy of C225 together with anti-human RNase 5 neutralization antibody or TKI
treatment using serum RNase 5 level as a predictive biomarker based on our study
can be examined in adequate animal models to see if it can be beneficial to clinical
practice in the future.

In our work, secretory ribonuclease including bovine RNase A and human
RNase 5 can promote cell migration and invasion, while they cannot induce cell
proliferation on 2D culture like conventional EGFR ligands including EGF and HBEGF. These partial overlapped but distinct biological effects between these two
families of ligands implicate that RNases may trigger certain signaling pathways and
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gene expression patterns different from typical EGFR ligands. An outstanding
question is how those ligands can provoke different biological functions and gene
expression by binding to and activating the same receptor. More comprehensive
analysis of gene expression such as cDNA microarray and RNA sequencing can be
performed in the future to characterize and compare gene expression signatures
induced by RNases and conventional EGFR ligands. It will provide a molecular
basis for us to study how these ligands can trigger different biological effects
through the same receptor activation. Since EGFR activation can promote an array
of biological function including anchorage-independent growth, angiogenesis and
stem-like properties, it would be worthwhile to examine if RNases can trigger these
particular effects through activating EGFR signaling. More efforts to answer these
types of questions will provide more solid evidence to depict the biological role of
RNase A and RNase 5 as ligands of EGFR in physiology and cancer biology.

Human RNase 5 is characterized to promote angiogenesis both in vitro and in
vivo. In our hands, it can stimulate pancreatic cancer cell migration and invasion,
leading to EMT process through EGFR activation. During the process, the tumor
cell viability is not affected by ribonuclease treatment in a significant level. However,
the same stimulation may exert different impact to other type of cells. An interesting
finding was made in previous studies that human ribonuclease 5 can suppress
immune cells including B and T cell proliferation in vitro, and the same feature was
also observed with bovine RNase A treatment although the effect is milder
(Matousek et al., 1995; Soucek et al., 1999; Sun et al., 2013). It would be interesting
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to ask if increased ribonuclease expression can interfere or impair immune function
in vivo, especially during the tumor initiation and progression. Based on previous
studies from other groups and our finding, ribonuclease activity and human RNase
5 expression could be elevated in pancreatic cancer patient serum, and it may
aggravate cancer progression through two arms: one arm is to activate EGFR
signaling of tumor cells to increase their motility and aggressiveness through
autocrine or paracrine manner, and the other arm is to block appropriate immune
response to eliminate tumor cells. This hypothesis is in need of more experiments
both in vitro and in vivo to validate in the future.
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